Publication: Encorafenib and binimetinib followed by radiotherapy for patients with BRAF<SUP>V600</SUP>-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)
No Thumbnail Available
Identifiers
Date
2024-07-01
Authors
Marquez-Rodas, Ivan
Alvarez, Ana
Arance, Ana
Valduvieco, Izaskun
Berciano-Guerrero, Miguel-angel
Delgado, Raquel
Soria, Ainara
Lopez-Campos, Fernando
Sanchez, Pedro
Romero, Jose Luis
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Abstract
Background. Encorafenib plus binimetinib (EB) is a standard-of-care treatment for advanced BRAF(V600)-mutant melanoma. We assessed the efficacy and safety of encorafenib plus binimetinib in patients with BRAF(V600)-mutant melanoma and brain metastasis (BM) and explored if radiotherapy improves the duration of response. Methods. E-BRAIN/GEM1802 was a prospective, multicenter, single-arm, phase II trial that enrolled patients with melanoma BRAF(V600)-mutant and BM. Patients received encorafenib 450 mg once daily plus binimetinib 45 mg BID, and those who achieved a partial response or stable disease at first tumor assessment were offered radiotherapy. Treatment continued until progression. Primary endpoint was intracranial response rate (icRR) after 2 months of EB, establishing a futility threshold of 60%. Results. The study included 25 patients with no BM symptoms and 23 patients with BM symptoms regardless of using corticosteroids. Among them, 31 patients (64.6%) received sequential radiotherapy. After 2 months, icRR was 70.8% (95% CI: 55.9-83.1); 10.4% complete response. Median intracranial progression-free survival (PFS) and OS were 8.5 (95% CI: 6.4-11.8) and 15.9 (95% CI: 10.7-21.4) months, respectively (8.3 months for icPFS and 13.9 months OS for patients receiving RDT). Most common grades 3-4 treatment-related adverse event was alanine aminotransferase (ALT) increased (10.4%). Conclusions. Encorafenib plus binimetinib showed promising clinical benefit in terms of icRR, and tolerable safety profile with low frequency of high-grade TRAEs, in patients with BRAFV600-mutant melanoma and BM, including those with symptoms and need for steroids. Sequential radiotherapy is feasible but it does not seem to prolong response.
Description
MeSH Terms
Proto-Oncogene Proteins B-raf
Alanine Transaminase
Progression-Free Survival
Medical Futility
Brain Neoplasms
Steroids
Adrenal Cortex Hormones
Alanine Transaminase
Progression-Free Survival
Medical Futility
Brain Neoplasms
Steroids
Adrenal Cortex Hormones
DeCS Terms
Radioterapia
Encéfalo
Supervivencia sin progresión
Inutilidad médica
Metástasis de la neoplasia
Corticoesteroides
Encéfalo
Supervivencia sin progresión
Inutilidad médica
Metástasis de la neoplasia
Corticoesteroides
CIE Terms
Keywords
Brain metastasis, Encorafenib and binimetinib, Melanoma, Radiotherapy, Targeted therapy
Citation
Márquez-Rodas I, Álvarez A, Arance A, Valduvieco I, Berciano-Guerrero MÁ, Delgado R, et al. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study). Neuro Oncol. 2024 Nov 4;26(11):2074-2083